The Nephrology landscape is buzzing with innovation!  Major players like Novartis, Vertex, Otsuka, and Regulus are making significant strides in clinical trials, while cutting-edge novel modalities and technologies are being tested in preclinical studies by Arbor Biotech, Maze Therapeutics, and ProteinQure to name a few.

The Rare & Genetic Kidney Disease Drug Development Summit returned for its 5th year to unite the leading minds of the renal renaissance from biopharma and regulators to academic key opinion leaders and patient advocacy groups. This meeting harnessed the energy and dedication to real impactful advancements in rare renal drug development with patients at the forefront.

Attendees joined us at the 2025 meeting to gain insights from 25+ expert speakers who covered the entire spectrum of rare renal drug development, from discovery and preclinical to clinical development. At the summit, attendees participated in three dedicated workshops for active discussion on key topics including target identification, mechanistic biology, kidney-on-a-chip models, trial design, recruitment & retention strategies, and patient empowerment. This comprehensive program spanned a broad spectrum of renal programs, including FSGS, PKD, Alport Syndrome, and IgAN, among others. 80+ industry experts helped attendees to access exclusive insights into therapeutic development across the rare renal field and bring actionable learnings and competitive intelligence back to their teams.